1. Executive Summary (Confidence: High)

Comphya SA, an EPFL spin-off based in Lausanne, is pioneering a paradigm shift in the treatment of erectile dysfunction (ED) by moving from compensatory therapies to nerve-restoring neuromodulation.^[12] Its flagship product, CaverSTIM, is an implantable pulse generator (IPG) that delivers direct electrical stimulation to the cavernous nerves responsible for penile erection.^[14] This technology is primarily aimed at the approximately 400,000 men who undergo radical prostatectomy each year in the U.S. and Europe, a large portion of whom suffer from long-term ED despite nerve-sparing surgical techniques.^[13] Comphya has successfully validated its technology through a first-in-man pilot study in Australia, which demonstrated a 90% erectile function recovery rate by nine months without safety concerns.^[13] The company is currently executing a global clinical development program, including an FDA-approved Investigational Device Exemption (IDE) study in the United States and trials in Brazil.^[17] With approximately $16.^[8] million in total funding and a recent Series A round, Comphya is positioned to introduce a smarter, integrated solution that fits directly into existing robotic surgical workflows.^[19]